IMNM Healthcare

Immunome, Inc.

$20.31+3.68%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.4B USD
Enterprise value: 1.8B USD
Full-time employees: 247

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 2.56 vs a peer median of 0.63)bigger price swings (beta 2.56 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 836% from December 2022 to August 2026.
Immunome had 836% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Immunome had 836% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 370% of revenue in 2025.
Immunome paid employees $26M in stock in 2025, 370% of its $7M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Immunome looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Immunome reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

27/ 100

Oct 5 30 → Nov 4 27 (-3)

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-14.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-9.5%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield22.8%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

8/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

12-month revenue fell 100.0%

Why

Weaker than most peers on:

▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth-100.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

3/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-3228.8%

Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-45.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -8.69Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-69.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.39Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-48.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.56

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio15.08×

SEC filings · latest balance sheetReported value33% base weight · Z-score 9.02Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.01×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.04Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Immunome

Is Immunome getting weaker?: Its latest SEC filing (Aug 11, 2026) got weaker in some ways: 12-month revenue fell 100.0%. Its overall score is unchanged at 27/100 since Oct 28, 2026.
How is Immunome valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.0% vs peers 1.5% (weaker than 100% of peers).
Is Immunome growing?: More slowly than most of its peers. Growth scores 8/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).
How profitable is Immunome?: Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -3228.8% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3228.8% vs peers 7.1% (weaker than 100% of peers).
How risky is Immunome?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 15.08× vs a peer median of 2.59× (stronger than 93% of peers).Current ratio 15.08× vs peers 2.59× (stronger than 93% of peers). Beta 2.56 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.56 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 100.0%

Worth watching: Immunome is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4.0M USD	0 USD	turned negative
Net income (12 months)	−224.6M USD	−254.3M USD	+13.2%
Free cash flow (12 months)	−205.5M USD	−219.1M USD	+6.6%
Cash	582.7M USD	217.7M USD	−62.6%
Shares outstanding	113.3M	113.6M	+0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	-781.4%	-3382.4%	-3228.8%	▲ 154 pts
Net margin	—	—	-761.9%	-3240.4%	-3060.0%	▲ 180 pts
Return on assets (ROA)	-42.7%	-153.4%	-71.9%	-121.9%	-31.1%	▲ 91 pts
Return on equity (ROE)	-51.3%	-221.6%	-89.1%	-161.7%	-33.5%	▲ 128 pts
Free cash flow margin	—	—	-59.9%	-1304.8%	-2890.1%	▼ >999 pts
Current ratio	5.82×	3.09×	6.63×	4.08×	14.69×	▲ 260%
Debt to equity	—	—	—	—	—	—
Interest coverage	—	—	—	—	—	—

IMNM price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 2.56 vs a peer median of 0.63)bigger price swings (beta 2.56 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 836% from December 2022 to August 2026.

Immunome had 836% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Immunome had 836% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 370% of revenue in 2025.

Immunome paid employees $26M in stock in 2025, 370% of its $7M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Immunome looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Immunome reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Immunome

Is Immunome getting weaker?

Its latest SEC filing (Aug 11, 2026) got weaker in some ways: 12-month revenue fell 100.0%. Its overall score is unchanged at 27/100 since Oct 28, 2026.

How is Immunome valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.0% vs peers 1.5% (weaker than 100% of peers).

Is Immunome growing?

More slowly than most of its peers. Growth scores 8/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).

How profitable is Immunome?

Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -3228.8% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3228.8% vs peers 7.1% (weaker than 100% of peers).

How risky is Immunome?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 15.08× vs a peer median of 2.59× (stronger than 93% of peers).Current ratio 15.08× vs peers 2.59× (stronger than 93% of peers). Beta 2.56 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.56 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4.0M USD

0 USD

turned negative

Net income (12 months)

−224.6M USD

−254.3M USD

+13.2%

Free cash flow (12 months)

−205.5M USD

−219.1M USD

+6.6%

Cash

582.7M USD

217.7M USD

−62.6%

Shares outstanding

113.3M

113.6M

+0.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-781.4%

-3382.4%

-3228.8%

▲ 154 pts

Net margin

—

-761.9%

-3240.4%

-3060.0%

▲ 180 pts

Return on assets (ROA)

-42.7%

-153.4%

-71.9%

-121.9%

-31.1%

▲ 91 pts

Return on equity (ROE)

-51.3%

-221.6%

-89.1%

-161.7%

-33.5%

▲ 128 pts

Free cash flow margin

—

-59.9%

-1304.8%

-2890.1%

▼ >999 pts

Current ratio

5.82×

3.09×

6.63×

4.08×

14.69×

▲ 260%

Debt to equity

—

Interest coverage

—